IL4 and Alzheimer disease: To further examine whether combination treatment with baricitinib or JTE-052 and tapinarof improves the IL-4-induced downregulation of FLG and LOR expression, which partially recapitulates keratinocytes in AD [9], NHEKs were exposed to IL-4 (50 ng/mL) in the presence or absence of baricitinib (1 μM) or JTE-052 (1 μM) and tapinarof (500 nM) for qRT-PCR and Western blotting analyses of FLG and LOR.